

## Bosulif - (100,500 mg; Tablet, Oral)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Bosutinib  | <b>Innovator</b>            | Pfizer              |
| <b>Dosage</b>                | 100,500 mg; Tablet, Oral   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5  | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Bosulif - (400 mg, tablet, oral)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Bosutinib  | <b>Innovator</b>            | Pfizer              |
| <b>Dosage</b>                | 400 mg, tablet, oral   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | None   | <b>Known Para IV Filers</b> | None                |
| <b>Other ANDA developers</b> | Less Than 5  | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Indicated for the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML) as well as for chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.